The next generation iCare HOME2 self-tonometer, developed by Icare Finland, has been launched.
According to Icare Finland, the iCare HOME2 provides “unsurpassed ease of use and accuracy” in monitoring real-world intraocular pressure (IOP) behaviour outside the doctor’s office and clinical hours, supporting glaucoma management.
Using iCare HOME2 and PATIENT2, the patient can actively participate in the care process by providing valuable information to the healthcare professional
Glaucoma is a chronic, progressive disease of the optic nerve. As IOP is the only modifiable risk factor for glaucoma progression, disease management is centred around its reduction. Therefore, comprehensive and accurate information on peak IOPs and IOP fluctuation patterns is crucial.
Most patients can use iCare HOME2 by following the advice and guidance in the instruction materials, freeing up health care professionals’ precious time.
“iCare HOME2’s smart light guide helps the patient in positioning the device correctly and in making the measurements effortlessly and accurately, every time. It is now easier than ever for doctors to provide glaucoma management based on real-world IOP information, from finding the optimal medication and instillation schedule, to assessing the need for and effectiveness of surgery,” the company states.
Patients can then use the iCare PATIENT2 mobile app, to follow their own IOP trends from an iOS or Android mobile device and send the IOP measurement results to their healthcare professional for review in the cloud based iCare CLINIC software. Using iCare HOME2 and PATIENT2, the patient can actively participate in the care process by providing valuable information to the healthcare professional. iCare says that by using HOME2, patient motivation for medication compliance can improve, and knowledge of the real-time IOP levels provides daily reassurance.
